Jubilant Pharmova Shows Strong Earnings Growth in Q2 2024

Jubilant Pharmova Ltd reported a 65% increase in consolidated net profit to Rs 102.5 crore for Q2 2024, driven by strong revenue growth. The company's consolidated revenue rose to Rs 1,752.3 crore. Jubilant Pharma Holdings Inc. also prepaid a USD 25 million term loan.

Jubilant Pharmova Ltd has reported a significant 65% growth in its consolidated net profit, reaching Rs 102.5 crore for the second quarter of 2024, showcasing the company's strong financial performance.

This growth is attributed to an increase in consolidated revenue, which stood at Rs 1,752.3 crore, compared to Rs 1,680.3 crore in the same period a year ago.

In a related development, Jubilant Pharma Holdings Inc., a subsidiary in the USA, voluntarily prepaid a USD 25 million term loan using internal funds, further reflecting the firm's healthy financial status.

(With inputs from agencies.)